• Molecular NamePhenoxybenzamine
  • SynonymFenossibenzamina [Dcit]; Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine Hcl; Phenoxybenzamine Hydrochloride; Phenoxybenzaminum [INN-Latin]; POB HCl
  • Weight303.833
  • Drugbank_IDDB00925
  • ACS_NO59-96-1
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.32
  • pkaN/A
  • LogD (pH=7, predicted)4.3
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.88
  • LogSw (predicted, AB/LogsW2.0)0.06
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds8
  • TPSA12.47
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-specific, irreversible alpha blocker.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability25.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolism of phenoxybenzamine includes N-dealkylation, O-dealkylation and aromatic hydroxydation.It was established that deschloroethyl-phenoxybenzamine showed weak alpha-adrenergic blocking activity as evidenced by decreased pressor responses to norephedrione.
  • Half life24 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A